Dataset Information


Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator.

ABSTRACT: The purposes of this study are to investigate the cost-effectiveness of an implantable carotid body stimulator (Rheos; CVRx, Inc, Minneapolis, MN) for treating resistant hypertension and determine the range of starting systolic blood pressure (SBP) values where the device remains cost-effective. A Markov model compared a 20-mm Hg drop in SBP from an initial level of 180 mm Hg with Rheos to failed medical management in a hypothetical 50-year-old cohort. Direct costs (2007$), utilities, and event rates for future myocardial infarction, stroke, heart failure, and end-stage renal disease were modeled. Sensitivity analyses tested the assumptions in the model. The incremental cost-effectiveness ratio (ICER) for Rheos was $64,400 per quality-adjusted life-years (QALYs) using Framingham-derived event probabilities. The ICER was <$100,000 per QALYs for SBPs > or =142 mm Hg. A probability of device removal of <1% per year or SBP reductions of > or =24 mm Hg were variables that decreased the ICER below $50,000 per QALY. For cohort characteristics similar to Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure-Lowering Arm (ASCOT-BPLA) participants, the ICER became $26,700 per QALY. Two-way sensitivity analyses demonstrated that lowering SBP 12 mm Hg from 220 mm Hg or 21 mm Hg from 140 mm Hg were required. Rheos may be cost-effective, with an ICER between $50,000 and $100,000 per QALYs. Cohort characteristics and efficacy are key to the cost-effectiveness of new therapies for resistant hypertension .

PROVIDER: S-EPMC3690459 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC6457112 | BioStudies
| S-EPMC4178167 | BioStudies
| S-EPMC5018997 | BioStudies
| S-EPMC6349519 | BioStudies
| S-EPMC6899870 | BioStudies
| S-EPMC2875154 | BioStudies
| S-EPMC3384486 | BioStudies
| S-EPMC8439195 | BioStudies
| S-EPMC6924863 | BioStudies
| S-EPMC7943717 | BioStudies